Navigation Links
CEL-SCI Corporation Releases Letter to Shareholders
Date:2/20/2009

ale following approval. We have also designed the facility to be used as a contract manufacturing facility during those times (e.g., during certain times in the Phase III study) when we will not be producing Multikine. This lucrative business could quickly become a multi-million dollar revenue generator for CEL-SCI.

  • We presented very promising data on a new rheumatoid arthritis vaccine discovered by CEL-SCI scientists. The data presented was as good as that achieved with Enbrel, a leading treatment for rheumatoid arthritis.

  • We started planning and pricing our global clinical trial designed to lead to marketing approval for Multikine. The recent strength of the dollar will reduce our Phase III study costs by several million dollars.

While we are pleased by these accomplishments, we also recognize that there are major challenges due to the severe financial downturn. This downturn has affected all of us, but we have taken immediate action. We very quickly reduced our expenditures and expanded our discussions with various pharmaceutical companies for a world-wide Multikine partnership. Things are very difficult all around for most companies, but we are seeing new strength in the bigger biotechnology names. This will hopefully trickle down to the smaller ones like us as well. The huge buyouts in the industry, Pfizer buying Wyeth and Roche trying to buy Genentech, will add over $100 billion in liquidity to the industry, and that too should help us down the road.

Let me share with you how we at CEL-SCI are dealing with and planning for recovery from this financial downturn. In our opinion, during such a difficult time as this you cannot rely on one strategy alone. Therefore we are pursuing the following multi-pronged strategy. To
'/>"/>

SOURCE CEL-SCI Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. CEL-SCI Announces Expansion of Exclusive Licensing Agreement for Cancer Drug Multikine
2. CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect
3. CEL-SCI Expects to Take Delivery of New Manufacturing Facility on October 8, 2008
4. Data Suggest CEL-SCIs CEL-2000 Vaccine Prevents or Retards Permanent Damage of Rheumatoid Arthritis
5. CEL-SCI Corporation Reports First Quarter Financial Results
6. CEL-SCI Corporation Announces 2007 Financial Results
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
8. CEL-SCI to Present at Rodman & Renshaw 9th Annual Healthcare Conference
9. CEL-SCI CEO to Present at the International Society for Pharmaceutical Engineering 2007 Chesapeake BioShowcase
10. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
11. CEL-SCI CEO to Present Tomorrow at the Biotech / Pharma / Healthcare On-Line Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... AARP Foundation today announced it has established a ... severe cold weather that has gripped much of the nation. ... need; so to support these emergency relief efforts AARP and ... could mean up to $500,000 in aid. The matching program ...
(Date:1/15/2014)... , January 15, 2014 Shire plc (LSE: SHP, ... Office of Fair Trading (OFT) approval condition to the announced tender ... VPHM).   As a result of the waiver, the ... to complete the tender offer on January 24, 2014 following the ...
(Date:1/15/2014)... 2014  In an unprecedented effort to curb the spread of "superbugs" ... transport vehicles, an advanced and portable UV germicidal lamp manufactured by ... time. In order to prevent EMS paramedics and ... West Palm Beach Fire Rescue is the first ...
Breaking Medicine Technology:AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Superbugs No Longer Ride In Rescue Vehicles 2
... 2011 Generex Biotechnology Corporation (OTCBB: GNBT) ( ... subsidiary Antigen Express, Inc. ( www.antigenexpress.com ) presented ... with an off-the-shelf immunotherapeutic cancer vaccine, AE37, in ... Sixth Annual ImVacS: The Immunotherapeutics and Vaccine Summit ...
... Inc. (Nasdaq: REGN ) today announced that clinical ... will be presented at the upcoming American Society of Retina ... 22, 2011 in Boston, Massachusetts. The presentations ... Phase 3 VIEW 1 and VIEW 2 Studies Comparing VEGF ...
Cached Medicine Technology:Generex Subsidiary Antigen Express Provides Update on Phase 2 Breast Cancer Immunotherapy Program 2Generex Subsidiary Antigen Express Provides Update on Phase 2 Breast Cancer Immunotherapy Program 3Generex Subsidiary Antigen Express Provides Update on Phase 2 Breast Cancer Immunotherapy Program 4Regeneron Announces Clinical Presentations at ASRS 2011 Annual Meeting 2Regeneron Announces Clinical Presentations at ASRS 2011 Annual Meeting 3
(Date:4/22/2014)... have characterized a set of clock genes that drive ... of species, from flies to humans. Over 15 mammalian ... are more. A team from the Perelman School of ... approaches could find them. , To accelerate clock-gene ... of Pharmacology and first author Ron Anafi, MD, PhD, ...
(Date:4/22/2014)... April 22, 2014 Researchers at UT Southwestern Medical ... from depression . , A team of ... by which ghrelin (a hormone with natural anti-depressant properties) ... potentially powerful new treatment for depression in the form ... The study, published online in April,s issue of ...
(Date:4/22/2014)... Calif.) The risk of pregnancy among women using ... is more than 10 times greater over a 10-year ... a study by researchers at Yale University and UC ... the medical journal Contraception , the study found ... method marketed under the brand name Essure. , ...
(Date:4/22/2014)... Washington, DC (April 22, 2014) The International ... May 22-26 in Seattle, Washington. The theme of ... life" means in a networked and digital society. ... and attended by over 2,200 Communication scholars representing ... largest scholarly international communication conference in the world. ...
(Date:4/22/2014)... is the standard measurement for assessing glycemic control over ... are typically measured every few months in a laboratory, ... accurately estimates A1c using self-monitored blood glucose (SMBG) readings, ... ( DTT ), a peer-reviewed journal from Mary Ann ... the DTT website at http://www.liebertpub.com/dtt . ...
Breaking Medicine News(10 mins):Health News:Bioinformatics profiling identifies a new mammalian clock gene 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 3Health News:Risk of pregnancy greater with newer method of female sterilization 2Health News:Risk of pregnancy greater with newer method of female sterilization 3Health News:International Communication Association to hold Annual Conference in Seattle, Washington 2
... suggests , , FRIDAY, Nov. 21 (HealthDay News) -- The season ... asthma, new research suggests. , Babies born in autumn -- about ... almost a 30 percent increased risk of asthma compared to babies ... the first December issue of the American Journal of Respiratory ...
... not given adequate drug therapy. This is the result of ... rzteblatt International ( Dtsch Arztebl Int 2008; 105[45]: ... this prospective, one-year survey. , 512 doctors in Germany took ... of whom 89.2% suffered from one or more cardiovascular diseases ...
... HUN ) today announced that its Founder and Chairman, ... American Cancer Society to,receive this year,s Medal of Honor, its ... who have made outstanding contributions to the,fight against cancer. , ... and his wife Karen Huntsman have "raised or,personally contributed over ...
... Nov. 21 Massachusetts Mutual Life,Insurance Company (MassMutual) ... Officers. , ... Vice President,and Chief Investment Officer, will assume the ... who remains Chairman and Chief Executive,Officer. Additionally, Mr. ...
... STOUGHTON, Mass., Nov. 21 Cardiosolutions, Inc.,( http://www.cardiosolutionsinc.com ... M.D., Ph.D. to the position of Chief Surgical ... Center for Aortic Surgery and Director of the,Marfan ... Department of,Thoracic and Cardiovascular Surgery at Cleveland Clinic. ...
... located in,Pittsburgh PA, and a subsidiary of Draeger, ... it believes are unsubstantiated allegations from,Sperian Respiratory Protection ... the popular Draeger PSS7000 SCBA (Self-Contained Breathing,Apparatus) used ... Draeger has a strong respect for intellectual ...
Cached Medicine News:Health News:Autumn Babies More Prone to Asthma 2Health News:Autumn Babies More Prone to Asthma 3Health News:Jon M. Huntsman Receives American Cancer Society Medal of Honor 2Health News:MassMutual Announces Promotions for Two Co-Chief Operating Officers 2Health News:MassMutual Announces Promotions for Two Co-Chief Operating Officers 3Health News:MassMutual Announces Promotions for Two Co-Chief Operating Officers 4Health News:MassMutual Announces Promotions for Two Co-Chief Operating Officers 5Health News:Cardiosolutions Names Dr. Lars Svensson Chief Surgical Officer 2Health News:Draeger Counters What It Believes Are Unsubstantiated Allegations of Patent Infringement by Sperian 2
Phacoemulsification system is a complete anterior segment surgical instrument. Its simplified design and unique innovations provide optimal surgical performance....
A gentle yet highly effective corneal rust ring remover with Alger brush of 1mm burr. Runs off 1 x AA battery, no switches, simply spin mandrel to operate....
Foreign body removal system. Designed to aid in the removal of foreign bodies and corneal rust rings....
Foreign body removal system. Designed to aid in the removal of foreign bodies and corneal rust rings. Ophtho-burr handpiece only. Battery powered handpiece....
Medicine Products: